Navigation Links
Micromet and Nycomed Begin Formal Preclinical Safety Studies for Antibody MT203 for Inflammatory and Autoimmune Diseases
Date:6/24/2008

y is MT293 which is licensed to TRACON Pharmaceuticals, Inc. and is being developed in a phase 1 clinical trial for the treatment of patients with cancer. Three additional BiTE antibodies, targeting CD33, CEA and MCSP, are in preclinical development. In addition, Micromet has established a collaboration with Nycomed for the development and commercialization of MT203, a human antibody neutralizing the activity of granulocyte/macrophage colony stimulating factor (GM-CSF), which has potential applications in the treatment of various inflammatory and autoimmune diseases, such as rheumatoid arthritis, psoriasis, or multiple sclerosis.

Forward-Looking Statements

This release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Factors that may cause actual results to differ materially from any future results expressed or implied by any forward-looking statements include the risk that product candidates that appeared promising in early research, preclinical studies or clinical trials do not demonstrate safety and/or efficacy in subsequent clinical trials, the risk that encouraging results from early research, preclinical studies or clinical trials may not be confirmed upon further analysis of the detailed results of such research, preclinical study or clinical trial, the risk that additional information relating to the safety, efficacy or tolerability of our product candidates may be discovered upon further analysis of preclinical or clinical trial data, the risk that we or our collaborators will not obtain approval to market our product candidates, the risks associated with reliance on outside financing to meet capital requirements, and the risks associated with reliance on collaborators, including MedImmune, Merck Serono, TRACON and Nycomed, for the funding or condu
'/>"/>

SOURCE Micromet, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Micromet Announces Changes in Management Team
2. Micromet Announces the Publication of BiTE Antibody Review in Drugs of the Future
3. Micromet Announces Presentation of Five Posters Related to Its Proprietary BiTE Antibody Platform at Annual Meeting of American Association for Cancer Research
4. Micromet Demonstrates That the Antibodies in Commercial Products Herceptin, Erbitux, Vectibix and Xolair Can Be Converted Into Highly Potent, T Cell- Engaging BiTE Antibodies
5. Micromet Presents Safety and Efficacy Data from Primate Studies With Two New BiTE Antibodies Developed for Treatment of Leukaemia and Melanoma
6. Micromet Shows Feasibility of Subcutaneous Delivery of BiTE Antibody in Preclinical Primate Study
7. Micromet Enrolls First Patient in a Phase 1 Clinical Trial with MT110, the First BiTE Antibody for Treatment of Solid Tumors
8. Micromet to Present Clinical Update for BiTE Antibody MT103/MEDI-538 at the International Conference on Malignant Lymphomas
9. Micromets BiTE Antibody Blinatumomab (MT103/MEDI-538) Demonstrates Durable Responses in Patients with Relapsed Non-Hodgkins Lymphoma
10. Micromet and MedImmune Commence Treatment in Phase 2 Trial of BiTE Antibody Blinatumomab (MT103/MEDI-538) in Patients with Acute Lymphoblastic Leukemia
11. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... July 10, 2014  Breg, Inc., a premier ... launched the FreeRunner™ knee brace with new innovations ... patella mal-tracking return to active lifestyles.  FreeRunner,s patent-pending ... braces, providing support when patients need it most, ... don,t. Patellofemoral issues are the most ...
(Date:7/10/2014)... , July 10, 2014  BC Technical, the largest ... MiE America , Inc., a leading provider of Siemens ... a long-term agreement naming BC Technical as the authorized ... MiE and BC Technical announced today that ... establish BC Technical as the service and systems provider ...
(Date:7/10/2014)... Israel , July 10, 2014   ... Diabetes Management Solution, today announced the appointment of ... independent member of its Board of Directors. ... legal and business experience to LabStyle as an ... and legal and corporate governance expert. He currently ...
Breaking Medicine Technology:Breg Introduces Knee Brace to Help Runners with Patellofemoral Pain Syndrome 2BC Technical Partners With MiE America To Be Authorized Provider Of Systems & Service 2LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 2LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 3LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 4
... 2011 /PRNewswire-Asia/ -- Simcere Pharmaceutical Group ("Simcere" or the ... company specializing in the development, manufacturing, and marketing of ... financial results for the fourth quarter and fiscal year ... Total revenue was RMB587.7 million (US$89.1 million) for ...
... board of directors of Hospira, Inc. (NYSE: HSP ... announced the election of F. Michael (Mike) Ball as the ... the board, effective March 28, 2011. Mr. Ball, 55, currently ... Begley, who will assume the role of executive chairman. ...
Cached Medicine Technology:Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2010 Results 2Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2010 Results 3Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2010 Results 4Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2010 Results 5Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2010 Results 6Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2010 Results 7Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2010 Results 8Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2010 Results 9Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2010 Results 10Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2010 Results 11Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2010 Results 12Hospira Board Names F. Michael Ball New CEO; Christopher B. Begley to Assume Executive Chairman Role 2Hospira Board Names F. Michael Ball New CEO; Christopher B. Begley to Assume Executive Chairman Role 3Hospira Board Names F. Michael Ball New CEO; Christopher B. Begley to Assume Executive Chairman Role 4
(Date:7/11/2014)... enterprises today are shifting towards the changing trend in ... offer these global enterprises a strategic method to cut ... operational costs to companies. The aim to minimize operational ... market driver for expanding the managed services market in ... estimated to grow from $142.75 billion in 2013 to ...
(Date:7/11/2014)... 11, 2014 As reported by the ... (Weintraub 7/11/14), a significant number of severe adverse events ... issues and even death from the highly-promoted and costly ... the Times report , a regulatory filing revealed ... by patients was almost 14% of prescriptions, up from ...
(Date:7/11/2014)... Wash.The largest study of its kind has found ... of advantages over their conventional counterparts, including more ... The study looked at an unprecedented 343 peer-reviewed ... organic and conventional plant-based foods, including fruits, vegetables, ... techniques to quantify differences between organic and non-organic ...
(Date:7/11/2014)... Steven Reinberg HealthDay ... A potential vaccine to protect children from the worldwide scourge ... Asian children. While the vaccine only prevented dengue fever ... full series of three shots, it protected more than 88 ... dengue fever can lead to hospitalization, and sometimes death. ...
(Date:7/11/2014)... Ticket Down is a reliable source for cheap ... in Wheatland, CA. In the Sacramento California area there ... Train Amphitheatre can do for music fans. The venue has ... of its existence and can seat 18,500 fans each night. ... metro area) will host the “That’s My Kind of Night” ...
Breaking Medicine News(10 mins):Health News:North America Managed Services Market Worth $68.65 Billion by 2018 - New Report by MicroMarket Monitor 2Health News:North America Managed Services Market Worth $68.65 Billion by 2018 - New Report by MicroMarket Monitor 3Health News:North America Managed Services Market Worth $68.65 Billion by 2018 - New Report by MicroMarket Monitor 4Health News:Acthar’s Deadly Adverse Events Revealed 2Health News:Acthar’s Deadly Adverse Events Revealed 3Health News:Major study documents nutritional and food safety benefits of organic farming 2Health News:Major study documents nutritional and food safety benefits of organic farming 3Health News:Dengue Fever Vaccine Shows Some Promise in Trial 2Health News:Dengue Fever Vaccine Shows Some Promise in Trial 3Health News:Luke Bryan Tickets Sleep Train Amphitheatre in Wheatland, CA (Sacramento): Ticket Down has Slashed Ticket Prices on Luke Bryan in Wheatland at Sleep Train 2Health News:Luke Bryan Tickets Sleep Train Amphitheatre in Wheatland, CA (Sacramento): Ticket Down has Slashed Ticket Prices on Luke Bryan in Wheatland at Sleep Train 3
... a key molecule that controls the growth, spread and survival ... toward new and better treatment options for pancreatic cancer . ... Beta molecule plays in pancreatic cancer and that they have ... and survival through its effect on NF Kappa B -- ...
... the drug alendronate (Fosamax) can reduce the risk of vertebral ... not osteoporosis. 3,737 postmenopausal women between ages 55 and 80 ... -2.5 were evaluated . About half the women randomly received ... thereafter while the other half took a placebo. ,The ...
... its growth factors aren’t just produced in the pancreas, but ... areas of the brain//, the result can be brain cell ... people with Alzheimer’s. ,The research was conducted in rats, ... IGF I and IGF II were produced in the nerve ...
... well known that HIV patients are at an increased risk ... study shows // aggressive antiretroviral therapy may help lower that ... antiretroviral therapy was associated with a lower incidence of Kaposi ... on more than 7,300 patients infected with HIV and the ...
... Intravenous administration of the drug tezosentan did not improve worsening ... failure // despite high hopes. The above fact was found ... to date. The study was conducted to evaluate if something ... order to speed up hospital discharge and prevent them from ...
... that how much we drink may be decided by a ... gene called DRD2 Taq1A(C32806T) polymorphism and social alcohol drinking may ... stronger gene of this type will tend to drink alcohol ... The gene is responsible for enhancing the pleasure that is ...
Cached Medicine News:
... The Perfect Single Vac Manifold ... 96-well plate in 30 minutes; ... an "open/closed" switch and a ... easy operation. contains vacuum chamber, ...
... Workstations from Caliper provide an automated alternative to Kuderna-Danish, Rotary, Vacuum-Style and Nitrogen Blow-Down Evaporators. For over ... world today. ... ... ...
QIAvac 96 is designed for efficient processing of QIAGEN 96-well plates....
For processing mini spin columns on QIAvac 6S;...
Medicine Products: